About the Vertex Innovation Awards

The Vertex Innovation Awards (VIA) programme is designed to support innovative clinical research in cystic fibrosis (CF) and applications for projects are welcomed from across the entire field of CF. The VIA programme seeks to support patient-oriented clinical research, including interventional, epidemiological and translational studies.

Announcing the 2017 VIA Awardees

Vertex are very pleased to announce the projects that were awarded VIA funding in 2017. We look forward to seeing the outcomes from these projects over the coming months.

Assessment of lung function with multivolume 1(h) MR imaging in young CF patients: comparison with radiological, functional and clinical indicators

Lead investigator: Andrea Aliverti, Politecnico di Milano, Italy

The aim of this study is to detect early functional alterations of multiple features of CF, comparing the results with traditional CT. The long-term view is to provide functional imaging biomarkers

ATP21A as a novel therapeutic target in cystic fibrosis lung disease

Lead investigator: Luis Galietta, Institute Giannina Gaslini, Italy

This study will investigate the role of ATP21A, further describing the localisation of expression and how it is regulated. The study will explore the relevance as a prognostic marker and potential pharmacological target

2018 Awardees

We are also happy to reveal that three successful applications have now been selected by the steering committee for the VIA 2018 awards. The winners will be announced later this year.

VIA 2019 Cycle

Vertex looks forward to continuing its commitment to scientific endeavour to meet unmet needs in CF with the proposed launch of the VIA 2019 cycle in the coming weeks.

For further information and to register your interest, please visit:

www.VertexInnovationAwards.com